Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 2;118(8):1062–1073. doi: 10.1038/s41416-018-0025-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. If you remix, transform, or build upon this article or a part thereof, you must distribute your contributions under the same license as the original. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/.

PMC Copyright notice

Fig. 3 — Combo score predicts for sensitivity of primary myeloma cells of patients to HDACi/DNMTi combined treatment. a Mononuclear cells from tumor samples of 10 patients with MM were cultured for 4 days in the presence of IL-6 (2 ng/ml) with or without graded decitabine and TSA concentrations. At day 4 of culture, the count of viable CD138⁺ MMCs was determined using flow cytometry. The gray columns represent the mean ± SD of primary myeloma cell counts (expressed as the percentage of the count without adding drugs) of the five patients with a low Combo score and the white columns that of the five patients with a high Combo score. b 5-Azacitidine and SAHA combination was also investigated using samples of 15 myeloma patients. The gray columns represent the mean ± SD of primary myeloma cell counts (expressed as the percentage of the count without adding drugs) of the 8 patients with a low Combo score and the white columns that of the 7 patients with a high Combo score